Alpha Tau Medical Ltd

NASDAQ DRTS

Data sourced from

and

Daily

Download Data

Alpha Tau Medical Ltd Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024: -3.18

Alpha Tau Medical Ltd Enterprise Value to EBITDA (EV/EBITDA) is -3.18 on June 03, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.

Alpha Tau Medical Ltd 52-week high Enterprise Value to EBITDA (EV/EBITDA) is -2.47 on May 02, 2024, which is 22.43% above the current Enterprise Value to EBITDA (EV/EBITDA).
Alpha Tau Medical Ltd 52-week low Enterprise Value to EBITDA (EV/EBITDA) is -3.86 on March 20, 2024, which is -21.21% below the current Enterprise Value to EBITDA (EV/EBITDA).
Alpha Tau Medical Ltd average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is -3.23.

NASDAQ: DRTS

Alpha Tau Medical Ltd

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street, Jerusalem, Israel, 9777605
Employees	121
Sector	Healthcare
Industry	Biotechnology

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends